PHYTOCHEMICAL PROFILE WITH ANTI-TUMOR ACTIVITY ESTIMATION OF CRUDE EXTRACT, ESSENTIAL OIL AND D-LIMONENE FROM CITRUS AURANTIUM L. AGAINST EHRLICH CARCINOMA
Objective: Plant based drugs have been a solution in the search for more cost-effective and less harmful drugs for the treatment of neoplasia. Citrus aurantium L. (Rutaceae) is abundant in Brazil and D-limonene, a monoterpene used in the prevention and treatment of neoplasia, was identified as a major compound in the oil of this specie. Objective of current study includes estimation of anti-tumor activity of Citrus aurantium L. (Rutaceae) (crude extract, essential oil and D-limonene) against Ehrlich carcinoma, as well as their phytochemical evaluation (D-limonene and essential oil).
Methods: There was a randomized non-clinical trial in which were used adult male mice (Balb-C). Four groups of animals were used having 6 numbers of animal in each group. All groups were inoculated with the Ehrlich tumor and then received the treatment (control, crude extract, essential oil and D-limonene) by oral route daily (28 day treatment). Essential oil was obtained by hydro-distillation and analyzed by the means of GC (Gas Chromatography) that was attached to mass spectrometry. In last of the observations hemogram was obtained.
Results: Animals treated with the essential oil has shown no significant difference compared to the group treated with D-limonene. The group treated with crude extract had a growth inhibition close to the essential oil and D-limonene groups.
Conclusion: It´s concluded that the essential oil and the crude extract of Citrus aurantium, L. (Rutaceae) can become therapeutic agents because of their anti-tumor activity with no toxicity to the blood cells and have low cost of production. Further studies are necessary, so they can be used in the treatment of neoplasia in humans. The chromatographic and spectrometric analyzes indicated the presence of other components in smaller amounts in the essential oil, which suggests that they could have a synergic activity to the D-limonene.
Peer Review History:
Received 2 June 2020; Revised 25 June; Accepted 4 July, Available online 15 July 2020
UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.
Average Peer review marks at initial stage: 6.0/10
Average Peer review marks at publication stage: 8.0/10